SMS Pharmaceuticals Limited share price

SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. It offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The company exports its products to approximately 75 countries. SMS Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Hyderabad, India.Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - GeneralNSE: SMSPHARMAISIN INE812G01025

16 Oct 2026, 3:29 PM IST₹450.50▲ 25.55 (6.01%)

Market Cap₹ 4,219 Cr.
Current Price₹ 450.50
High / Low₹ 494 / 270
Stock P/E40.1
Book Value₹ 84
Dividend Yield0.09 %
ROCE13.7 %
ROE14.30 %
Face Value₹ 1.0

More figures (10)

EPS (TTM)₹ 11.24
Price / Book5.37
OPM15.1 %
Debt / Equity0.46
Sales growth (5Y)9.5 %
Profit growth (5Y)10.3 %
Promoter holding74.9 %
EV / EBITDA26.1
Beta0.28
All-time high₹ 494

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
SMSPHARMA	+11.80%	+16.38%	+6.15%	+45.14%	+54.27%	+55.24%	+24.93%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

SMS Pharmaceuticals Limited is in the Drug Manufacturers - General industry (Healthcare), with a market value of ₹4,219 crore.
It trades at 40.1 times its last 12 months' earnings and 5.4 times book value.
Revenue grew 9.5% a year over the last 5 years, profit 10.3% a year.
Return on equity was 14.3% and return on capital employed 13.7% in the latest year.
Debt was 0.46 times shareholders' equity.
The share price is 8.9% below its 52-week high and up 54.3% over one year.
Promoters and insiders hold about 74.9%; institutions about 2.9%.

Pros

Promoters have raised their holding by 3.75 points over 3 years, to 68.07%.
Promoters hold a large stake of 68.07%.

Cons

No standout weaknesses in the reported figures.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About SMS Pharmaceuticals Limited

Employees: 1,617
Head office: Hyderabad

HealthcareDrug Manufacturers - General

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	SMS Pharmaceuticals	450.50	40.1	4,219	0.09	21	2.04	207	5.57	13.7	14.3	5.37	15.1	0.46	74.88	887	9.5
2.	GlaxoSmithKline Pharmaceuticals	2,566.10	40.7	43,471	2.26	237	-9.77	938	-3.69	55.4	49.1	19.17	32.8	0.01	75.63	3,808	5.7
3.	Rubicon Research	1,508.60	86.9	24,973	0.10	85	133.91	534	49.20	23.6	19.1	19.32	20.6	0.24	69.15	1,731	36.6
4.	Sai Parenteral's	487.30	168.0	2,153	0.00	8	—	179	—	17.9	21.1	3.25	6.4	1.83	74.83	381	126.1
5.	CORONA Remedies	2,003.90	61.6	—	0.49	60	—	422	—	29.0	27.4	16.41	18.3	0.22	77.61	1,403	16.6
	Median: 5 Co.	1,508.60	61.6	14,596	0.10	60	2.04	422	5.57	23.6	21.1	16.41	18.3	0.24	74.88	1,403	16.6

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	135	167	161	246	164	197	173	248	196	242	210	238	207
YOY Sales Growth %	110.19%	4.52%	8.52%	64.50%	21.51%	18.07%	7.35%	0.98%	19.21%	23.22%	21.40%	-4.13%	5.57%
	109	139	132	212	131	165	140	207	157	194	167	198	166
Material Cost %	55%	59%	57%	65%	53%	59%	49%	60%	57%	58%	54%	56%	54%
Employee Cost %	10%	8%	9%	8%	10%	9%	11%	11%	9%	8%	10%	12%	11%
Other Expenses %	16%	16%	17%	13%	16%	16%	21%	13%	14%	14%	15%	15%	14%
Operating Profit	26	28	29	34	34	31	33	41	39	48	44	40	41
OPM %	19%	17%	18%	14%	20%	16%	19%	16%	20%	20%	21%	17%	20%
Other Income	1	1	1	2	1	1	2	1	1	1	4	3	2
Interest	6	6	6	6	5	5	4	5	6	6	6	5	5
Depreciation	8	8	8	8	8	9	9	9	10	10	10	10	10
Profit before tax	13	15	17	22	22	20	22	29	24	34	31	27	27
	31%	21%	26%	26%	25%	29%	24%	30%	23%	26%	26%	23%	26%
Current tax	3	3	4	5	5	5	5	5	5	8	7	5	6
Deferred tax	0	0	0	1	0	1	0	4	1	1	1	1	1
	9	12	11	17	16	14	18	20	20	25	23	33	21
Profit from associates	1	-0	-1	1	0	0	1	0	2	0	0	12	1
Profit to shareholders			11				18	120		25	23	33	21
YOY Profit Growth %			204.97%	177.87%	76.41%	20.25%	58.90%	17.57%	24.34%	79.53%	28.67%	61.03%	2.04%
EPS in Rs	1.10	1.39	1.36	2.04	1.95	1.69	2.15	2.40	2.31	2.84	2.59	3.58	2.23
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	135	167	161	246	164	197	173	248	196	242	210	238	207
YOY Sales Growth %	110.19%	4.52%	8.52%	64.50%	21.51%	18.07%	7.35%	0.98%	19.21%	23.22%	21.40%	-4.13%	5.57%
	109	139	133	212	131	165	140	207	157	194	167	198	165
Material Cost %	55%	59%	57%	65%	54%	59%	49%	59%	57%	58%	54%	56%	54%
Employee Cost %	10%	8%	9%	8%	10%	9%	11%	11%	9%	8%	10%	12%	11%
Other Expenses %	16%	16%	17%	13%	16%	16%	21%	13%	14%	14%	15%	15%	14%
Operating Profit	27	28	29	33	33	32	33	41	39	48	44	40	42
OPM %	20%	17%	18%	14%	20%	16%	19%	17%	20%	20%	21%	17%	20%
Other Income	1	1	1	2	1	1	2	1	1	1	4	3	2
Interest	6	6	6	6	5	5	4	5	6	6	6	5	5
Depreciation	8	8	8	8	8	9	9	9	10	10	10	10	10
Profit before tax	13	15	16	22	22	20	23	29	24	34	31	27	28
	29%	21%	26%	26%	25%	28%	24%	29%	24%	26%	25%	23%	25%
Current tax	3	3	4	5	5	5	5	5	5	8	7	5	6
Deferred tax	0	0	0	1	0	1	0	4	1	1	1	1	1
	9	12	12	16	16	14	17	21	18	25	23	21	21
YOY Profit Growth %		1,429.23%	142.12%	97.18%	75.90%	18.35%	41.07%	29.52%	11.51%	76.34%	35.90%	1.45%	16.07%
EPS in Rs	1.10	1.42	1.44	1.88	1.93	1.68	2.03	2.43	2.05	2.82	2.57	2.29	2.26
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2017	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
			412	563	520	522	709	783	887	898
YOY Sales Growth %				36.71%	-7.69%	0.42%	35.86%	10.36%	13.30%
			332	442	406	468	593	644	716	725
Material Cost %			60%	60%	53%	64%	60%	56%	56%	56%
Employee Cost %			10%	7%	10%	11%	9%	10%	10%	10%
Other Expenses %			11%	11%	15%	15%	15%	16%	15%	15%
Operating Profit			80	121	114	55	117	139	171	173
OPM %			19%	22%	22%	10%	16%	18%	19%	19%
Other Income			5	3	5	5	4	6	8	10
Interest			12	11	19	22	23	19	23	23
Depreciation			22	22	32	32	32	34	40	40
Profit before tax			51	91	68	5	66	92	117	119
			36%	33%	1%	27%	26%	27%	25%	25%
Current tax			9	16	15	-0	15	20	26
Deferred tax			9	14	-14	1	2	5	3
			33	63	62	-7	50	69	102	102
Profit from associates				2	-6	-11	1	2	14	13
Profit to shareholders								69	102	103
YOY Profit Growth %				91.28%	-0.49%	-111.35%		38.75%	47.52%
EPS in Rs	0.00	0.00	3.73	7.39	7.35	-0.83	5.89	8.16	11.15	11.24
Dividend Payout %								5%	3%

Compounded Sales Growth

5 Years:: 10%
3 Years:: 19%
TTM:: 10%

Compounded Profit Growth

5 Years:: 10%
TTM:: 40%

Stock Price CAGR

5 Years:: 25%
3 Years:: 55%
1 Year:: 54%

Return on Equity

4 Years:: 9%
Last Year:: 14%

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	95	95	465	412	563	520	522	709	783	887	898
YOY Sales Growth %			388.09%	-11.39%	36.71%	-7.69%	0.42%	35.86%	10.36%	13.30%
	79	79	375	332	442	405	467	592	643	716	724
Material Cost %	62%	62%	63%	60%	60%	53%	64%	60%	56%	56%	56%
Employee Cost %	8%	8%	8%	10%	7%	10%	11%	9%	10%	10%	10%
Other Expenses %	13%	13%	10%	11%	11%	15%	15%	15%	16%	15%	15%
Operating Profit	16	16	90	80	121	114	55	117	140	171	174
OPM %	17%	17%	19%	19%	22%	22%	10%	16%	18%	19%	19%
Other Income	0	0	3	5	3	5	5	4	6	8	10
Interest	3	3	12	12	11	19	22	23	19	23	23
Depreciation	5	5	19	22	22	32	32	32	34	40	40
Profit before tax	8	8	62	51	91	69	6	66	93	116	121
	-51%	-51%	34%	36%	33%	1%	26%	25%	27%	25%	25%
Current tax	3	3	13	9	16	15	-0	15	20	26
Deferred tax	-8	-8	8	9	14	-14	1	2	5	3
	12	12	41	33	61	68	4	49	68	88	91
YOY Profit Growth %			232.63%	-21.14%	86.50%	11.60%	-94.00%	1,110.03%	38.35%	28.12%
EPS in Rs	1.47	1.47	4.90	3.86	7.20	8.04	0.48	5.84	8.07	9.58	9.94
Dividend Payout %							62%	5%	5%	4%

Compounded Sales Growth

5 Years:: 10%
3 Years:: 19%
TTM:: 10%

Compounded Profit Growth

5 Years:: 8%
3 Years:: 178%
TTM:: 29%

Stock Price CAGR

5 Years:: 25%
3 Years:: 55%
1 Year:: 54%

Return on Equity

4 Years:: 9%
Last Year:: 14%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	8	8	9	9
Reserves	452	528	631	776
	254	281	311	365
Long term borrowings	121	122	139	172
Short term borrowings	131	158	171	193
	165	217	202	212
Trade payables	107	151	114	120
Minority interest			0	0
Current liabilities	255	332	324	353
Total Liabilities	880	1,034	1,153	1,362
	449	479	575	684
Gross block	610	668	797	945
Accumulated depreciation	160	190	222	261
Goodwill & intangibles	1	3	2	3
CWIP	39	44	44	153
	391	511	535	525
Inventories	223	234	285	351
Trade receivables	148	236	203	216
Cash & equivalents	7	36	41	46
Current assets	411	534	554	638
Total Assets	880	1,034	1,153	1,362

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	22	50	82	59
Profit for the year	-7	50	69	102
Working capital changes	-31	-55	-43	-94
Direct taxes paid	-5	-15	-20	-24
	-30	-52	-123	-131
Fixed assets purchased	-30	-52	-123	-131
Fixed assets sold	0	0	0
Investments purchased	-0	-0	-0	-0
	-32	31	47	76
Proceeds from borrowings	35	65	75	88
Repayment of borrowings	-43	-38	-44	-34
Interest paid	-21	-22	-17	-22
Dividends paid	-3	-3	-3	-4
Net Cash Flow	-39	29	5	4
Free Cash Flow	-7	-2	-42	-71

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	-1.5%	10.0%	11.8%	14.3%
ROCE	4.2%	12.6%	13.3%	13.7%
Operating margin	4.3%	12.1%	13.4%	15.1%
Net margin	-1.4%	7.1%	8.9%	11.5%
Debt / equity	0.55	0.52	0.49	0.46
Current ratio	1.61	1.61	1.71	1.81
Debtor days	104	122	95	89
Inventory days	209	171	201	219
Days payable	100	111	80	75
Cash conversion cycle	213	182	216	233
Working capital days	109	104	108	118

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 68.07%
FIIs 1.18%
DIIs 0.20%
Public 30.56%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	64.32%	64.67%	64.67%	64.67%	64.67%	66.26%	66.26%	68.07%	68.07%	68.07%	68.07%	68.07%
	0.59%	0.17%	0.17%	0.52%	0.31%	0.08%	0.03%	0.28%	0.04%	0.31%	0.65%	1.18%
Foreign portfolio investors (Cat. I)	0.59%	0.17%	0.12%	0.35%	0.21%	0.08%	0.03%	0.28%	0.04%	0.15%	0.45%	0.55%
Foreign portfolio investors (Cat. II)			0.06%	0.17%	0.10%					0.16%	0.20%	0.63%
		1.98%	2.13%	2.55%	2.55%	2.43%	3.03%	2.88%	3.21%	3.02%	2.83%	0.20%
Mutual funds		1.98%	2.13%	2.55%	2.55%	2.43%	3.03%	2.88%	3.21%	2.96%	2.81%
Alternative investment funds										0.05%	0.02%	0.19%
	35.09%	33.17%	33.03%	32.26%	32.47%	31.22%	30.67%	28.78%	28.69%	28.60%	28.45%	30.56%
Retail (up to ₹2 lakh)	21.23%	20.33%	20.55%	19.80%	20.45%	19.73%	19.30%	17.78%	17.85%	17.32%	17.46%	18.35%
HNIs (above ₹2 lakh)	7.99%	7.60%	7.26%	7.24%	6.93%	6.62%	6.59%	6.24%	6.23%	5.85%	6.58%	7.50%
NRIs	2.73%	2.72%	2.68%	2.71%	2.66%	2.53%	2.55%	2.43%	2.48%	3.01%	2.31%	2.16%
Bodies corporate	2.39%	1.75%	1.76%	1.74%	1.65%	1.60%	1.49%	1.62%	1.44%	1.73%	1.41%	1.85%
IEPF	0.07%	0.08%	0.08%	0.08%	0.08%	0.08%	0.08%	0.07%	0.06%	0.06%	0.06%	0.06%
No. of Shareholders	25,341	30,140	31,780	33,136	34,973	35,332	33,652	34,157	34,378	32,397	31,489	34,904

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 22 Sep 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

No recent coverage found.

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about SMS Pharmaceuticals Limited

What is the share price of SMS Pharmaceuticals Limited today?

SMS Pharmaceuticals Limited (SMSPHARMA) last traded at ₹450.50 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of SMS Pharmaceuticals Limited?

About ₹4,219 crore at the latest price.

What is the P/E ratio of SMS Pharmaceuticals Limited?

About 40.1 times its earnings over the last 12 months.

Is SMS Pharmaceuticals Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy SMS Pharmaceuticals Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

SMS Pharmaceuticals Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About SMS Pharmaceuticals Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about SMS Pharmaceuticals Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next